etherna immunotherapies nv logo

eTheRNA Immunotherapies NV

eTheRNA, spin-off from the ÇVrije Universiteit Brussel (VUB) developing mRNA-based immunotherapies for melanoma, triple negative breast cancer and infectious diseases.

eTheRNA was established on TriMix technology, developed at VUB Laboratory for Molecular and Cellular Therapy, headed by Prof. Kris Thielemans (and co-founders Carlo Heirman & Sonja Meirvenne) with Prof. Bart Neyns - Brussels University Hospital.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.etherna.be
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Galileilaan 192845
Niel
Belgium
Email
Contact Number

In July 2014, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology. In 2015, eTheRNA entered into a partnership with Progress Pharma.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/etherna-immunotherapeutics” connections=”true” suffix=””]

eTheRNAs TriMix contains three naked, injectable mRNA molecules (coding for naturally occurring proteins called CD40L, CD70 and constitutive active TLR4) that together generate a safer and potent enhancement of the patients own Çdendritic cell-mediated immune response against cancer or microbial antigens than any other similar approach investigated until now.

In March 2016, eTheRNA secured EUR 24 Mn in a Series A financing led by LSP Life Sciences Partners, PMV (Belgium), Omega Funds, Fund+ (Belgium) and Boehringer Ingelheim Venture Fund.